Garry Menzel

Garry Menzel

Director/Board Member at ADAPTIMMUNE THERAPEUTICS PLC

Net worth: 537 011 $ as of 31/03/2024

59 year
Health Technology
Consumer Services
Finance

Profile

Garry E.
Menzel
is currently the Director at Epilepsy Therapy Project.
He also holds current positions as an Independent Non-Executive Director at Adaptimmune Therapeutics Plc, an Independent Director at Stoke Therapeutics, Inc., an Independent Director at Black Diamond Therapeutics, Inc., a Member-National Board at Epilepsy Foundation, the Principal at Royal College of Art, and an Operating Partner at GHO Capital Partners LLP.
In his former roles, Dr. Menzel served as the President, Chief Executive Officer & Director at TCR2 Therapeutics, Inc. from 2016 to 2023.
He was also a Managing Director at Credit Suisse Group AG from 2004 to 2008 and at The Goldman Sachs Group, Inc. from 1994 to 2004.
Additionally, he held positions as the Chief Financial Officer at DaVita, Inc. from 2013 to 2015, the Chief Operating Officer at Regulus Therapeutics, Inc. from 2008 to 2013, and the Chief Strategy Officer at Axcella Health, Inc. from 2015 to 2016.
He has also worked as a Research Assistant at Smithkline Beecham Plc and as a Consultant at Bain & Co., Inc.Dr. Menzel's education includes an undergraduate degree from Imperial College London in 1985, a doctorate from the University of Cambridge, and an MBA from Stanford Graduate School of Business in 1994.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
16/05/2023 76,644 ( 0.15% ) 388 585 $ 31/03/2024
10/07/2023 563,522 ( 0.10% ) 148 426 $ 31/03/2024
01/09/2023 0 ( -.--% ) - $ 31/03/2024

Garry Menzel active positions

CompaniesPositionStart
BLACK DIAMOND THERAPEUTICS, INC. Director/Board Member 01/01/2014
STOKE THERAPEUTICS, INC. Director/Board Member 13/08/2020
ADAPTIMMUNE THERAPEUTICS PLC Director/Board Member 01/06/2023
Corporate Officer/Principal 01/01/2003
Epilepsy Therapy Project Director/Board Member -
Royal College of Art Corporate Officer/Principal 17/03/2010
Private Equity Investor 23/04/2024
All active positions of Garry Menzel

Former positions of Garry Menzel

CompaniesPositionEnd
TCR2 THERAPEUTICS INC. Chief Executive Officer 01/01/2023
AXCA HEALPAR Corporate Officer/Principal 01/09/2016
░░░░░░ ░░░░ ░░░░░░░░ ░░ ░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░ ░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
See the detail of Garry Menzel's experience

Training of Garry Menzel

Imperial College London Undergraduate Degree
University of Cambridge Doctorate Degree
Stanford Graduate School of Business Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Garry Menzel's experience

Connections

100 +

1st degree connections

19

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies6
DAVITA INC.

Health Services

THE GOLDMAN SACHS GROUP, INC.

Finance

REGULUS THERAPEUTICS INC.

Health Technology

AXCA HEALPAR

Health Technology

BLACK DIAMOND THERAPEUTICS, INC.

Health Technology

ADAPTIMMUNE THERAPEUTICS PLC

Health Technology

Private companies9

Health Technology

Finance

Commercial Services

Commercial Services

Commercial Services

Epilepsy Therapy Project

Health Technology

Stoke Therapeutics, Inc.

Finance

See company connections